Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple tumours. However, only a few patients respond to ICIs, …
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment | Nature Reviews Drug Discovery
Leave a Reply